p15 Polyclonal Antibody

    • Catalog No.:YT3492
    • Applications:WB;IHC;IF;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • p15
      • Fields:
      • >>FoxO signaling pathway;>>Cell cycle;>>Cellular senescence;>>TGF-beta signaling pathway;>>Cushing syndrome;>>Human T-cell leukemia virus 1 infection;>>Pathways in cancer;>>Viral carcinogenesis;>>Small cell lung cancer;>>Gastric cancer
      • Gene Name:
      • CDKN2B
      • Protein Name:
      • Cyclin-dependent kinase 4 inhibitor B
      • Human Gene Id:
      • 1030
      • Human Swiss Prot No:
      • P42772
      • Mouse Swiss Prot No:
      • P55271
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human p15 INK. AA range:89-138
      • Specificity:
      • p15 Polyclonal Antibody detects endogenous levels of p15 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:40000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • CDKN2B;MTS2;Cyclin-dependent kinase 4 inhibitor B;Multiple tumor suppressor 2;MTS-2;p14-INK4b;p15-INK4b;p15INK4B
      • Observed Band(KD):
      • 14kD
      • Background:
      • This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008],
      • Function:
      • disease:Defects in CDKN2B are involved in tumor formation.,function:Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.,polymorphism:Genetic variations in CDKN2B may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus.,similarity:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.,similarity:Contains 4 ANK repeats.,subunit:Heterodimer of CDKN2B with CDK4 or CDK6.,
      • Subcellular Location:
      • Cytoplasm . Also found in the nucleus.
      • Expression:
      • Isoform 2 is expressed in normal (keratinocytes, fibroblasts) and tumor cell lines.
      • Products Images
      • SIRT2 counteracts primate cardiac aging via deacetylation of STAT3 that silences CDKN2B. Nature Aging Guang-Hui Liu WB Mouse,Human 1:3000 hearts cardiomyocytes
      • Gao, Lei, et al. "Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition." Nature communications 10.1 (2019): 1665.
      • Western Blot analysis of various cells using p15 Polyclonal Antibody diluted at 1:500
      • Immunohistochemical analysis of paraffin-embedded Human Right kidney. 1, Antibody was diluted at 1:100(4° overnight). 2, High-pressure and temperature EDTA, pH8.0 was used for antigen retrieval. 3,Secondary antibody was diluted at 1:200(room temperature, 30min).
      • Immunofluorescence analysis of HeLa cells, using p15 INK Antibody. The picture on the right is blocked with the synthesized peptide.
      • Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using p15 INK Antibody. The picture on the right is blocked with the synthesized peptide.